Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Pet Monoclonal Antibodies Market

Pet Monoclonal Antibodies Market Share

Report ID: GMI10496
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Pet Monoclonal Antibodies Market Share

The market is characterized by numerous established players striving to capitalize on the growing demand for advanced pet healthcare solutions. Key players are dominating the market with their diverse portfolio of monoclonal antibodies and strong distribution networks. Also, collaborations between academic institutions and industry players for R&D further intensify competition. Furthermore, emerging startups are also making significant strides, leveraging innovative technologies and strategic partnerships to gain traction in this evolving market landscape

Pet Monoclonal Antibodies Market Companies

Few of the prominent players operating in the pet monoclonal antibodies industry providing commercial and pipeline products are:

Ceva Santé Animale
Boehringer Ingelheim International GmbH
Elanco Animal Health
Merck Animal Health
Sanofi
Vetigenics
Zoetis Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The pet monoclonal antibodies market size was valued at USD 967.3 million in 2023 and is estimated to grow at 14.2% CAGR from 2024 to 2032, owing to the rising incidence of chronic diseases.

The dog segment in the market recorded USD 715.9 million in 2023 and will grow at 14.1% CAGR during 2024-2032, driven by the high prevalence of chronic and infectious diseases among dogs.

U.S. pet monoclonal antibodies market size accounted for USD 432.9 million in 2023 and is anticipated to grow rapidly through 2032, owing to high pet ownership rates, and significant investment in R&D.

Ceva Santé Animale, Boehringer Ingelheim International GmbH, Elanco Animal Health, Merck Animal Health, Sanofi, Vetigenics, and Zoetis Inc. among others.